Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Akebia Therapeutics, Inc. AKBA

Set alert

Price alert · AKBA

All alert types
0.71 USD 0.00 +0.18%

As of Nov 3, 2:05 PM ET

Bid
0.71 × 2
Ask
0.71 × 2
0.7094 Day range 0.7474
0.542 52-week range 2.15
YTD
-55.92%
1 year
-66.52%
Open
0.7247
Prev close
0.7084
Mkt cap
196.58M
Vol
3.95M
Avg vol
7.88M
EPS
-0.12
P/E
0.00
Div yield
0.00%
More statistics
Low
0.7094
High
0.7474
Forward P/E
-7.15
Beta
0.73
Short ratio
4.71
Inst. own
27.33%
Dividend
0.00
Ex-div date
50-d avg
1.80
200-d avg
1.45
1y target
5.50

5D chart

Chart tools
Interval
1m5m15m30m

Signals (122)
NameTimeAgo
SMA: BearishNov 3, 1:35 PM30 minutes ago
MACD: Buy SignalNov 3, 1:30 PM35 minutes ago
SMA: BullishNov 3, 1:20 PM45 minutes ago
SMA: BearishNov 3, 11:50 AM2 hours ago
SMA: BearishNov 3, 11:30 AM2 hours ago
MACD: Sell SignalNov 3, 11:20 AM2 hours ago
RSI: OverboughtNov 3, 11:00 AM3 hours ago
RSI: OverboughtNov 3, 10:15 AM3 hours ago
RSI: OverboughtNov 3, 9:35 AM4 hours ago
SMA: BullishNov 2, 3:35 PM22 hours ago
SMA: BullishNov 2, 3:35 PM22 hours ago
SMA: BearishNov 2, 3:25 PM22 hours ago
SMA: BearishNov 2, 3:20 PM22 hours ago
SMA: BullishNov 2, 3:15 PM22 hours ago
SMA: BearishNov 2, 3:05 PM23 hours ago
SMA: BullishNov 2, 3:00 PM23 hours ago
SMA: BearishNov 2, 2:55 PM23 hours ago
SMA: BullishNov 2, 2:50 PM23 hours ago
SMA: BullishNov 2, 2:45 PM23 hours ago
MACD: Buy SignalNov 2, 2:45 PM23 hours ago

Newest 20 of 122.

Analyst view

Price target (mean) 5.50 +675.0% upside
Target (low)
4.00
Target (mean)
5.50
Target (high)
7.50
Ratings (0m) 3 3 buy · 0 hold · 0 sell
  • Strong buy2
  • Buy1
  • Hold0
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 3
  • 1 month ago 3
  • 2 months ago 3

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

AKBA analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.04-0.04 – -0.040.000.0%40.91M-27.2%1
Next quarter-0.075-0.15 – 0.00-0.0843+11.0%35.61M+9.2%2
Current year-0.26-0.26 – -0.26-0.2732+4.8%154.60M-20.6%1
Next year-0.195-0.47 – 0.08-0.26+25.0%177.96M+15.1%2

Upgrades and downgrades

The latest rating changes

AKBA analyst upgrades and downgrades
DateFirmActionFromTo
Oct 23, 2024HC Wainwright & Co.ReiteratedBuyBuy
Oct 10, 2024HC Wainwright & Co.ReiteratedBuyBuy
Oct 8, 2024HC Wainwright & Co.ReiteratedBuyBuy
Sep 6, 2024HC Wainwright & Co.ReiteratedBuyBuy
Aug 12, 2024HC Wainwright & Co.MaintainedBuyBuy
Mar 28, 2024HC Wainwright & Co.MaintainedBuyBuy
Mar 15, 2024HC Wainwright & Co.ReiteratedBuyBuy
Nov 17, 2023HC Wainwright & Co.MaintainedBuyBuy
Sep 27, 2023HC Wainwright & Co.ReiteratedBuyBuy
Aug 28, 2023HC Wainwright & Co.UpgradeNeutralBuy
Aug 11, 2023HC Wainwright & Co.ReiteratedNeutralNeutral
Jun 21, 2023HC Wainwright & Co.ReiteratedNeutralNeutral
Jun 14, 2023HC Wainwright & Co.ReiteratedNeutralNeutral
Jun 2, 2023HC Wainwright & Co.ReiteratedNeutralNeutral
May 31, 2023Piper SandlerUpgradeNeutralOverweight
May 30, 2023HC Wainwright & Co.ReiteratedNeutralNeutral
May 26, 2023HC Wainwright & Co.ReiteratedNeutralNeutral
May 9, 2023NeedhamReiterated—Neutral
Apr 26, 2023HC Wainwright & Co.Maintained—Neutral
Mar 31, 2023HC Wainwright & Co.Reiterated—Neutral
Mar 10, 2023HC Wainwright & Co.Reiterated—Neutral
Feb 22, 2023HC Wainwright & Co.Maintained—Neutral
May 16, 2022HC Wainwright & Co.Maintained—Neutral
Mar 31, 2022HC Wainwright & Co.DowngradeBuyNeutral
Mar 31, 2022NeedhamDowngradeBuyHold
Mar 31, 2022MizuhoDowngradeBuyNeutral
Mar 31, 2022Piper SandlerDowngradeOverweightNeutral
Nov 11, 2021HC Wainwright & Co.Maintained—Buy
Mar 8, 2021Cantor FitzgeraldInitiated—Overweight
Mar 8, 2021HC Wainwright & Co.Maintained—Buy